Isoflavones: Promising Natural Agent for Cancer Prevention and Treatment DOI Creative Commons

Muhammad Hammad Ul Hassan,

Muhammad Shahbaz, Muhammad Imran

et al.

Food Science & Nutrition, Journal Year: 2025, Volume and Issue: 13(3)

Published: March 1, 2025

ABSTRACT Isoflavones are currently being investigated by researchers in order to demonstrate their ability prevent the proliferation of cancer cells. The current review aimed potential isoflavones eliminate cancerous cells stomach, liver, lung, breast, and prostate, as anticancer properties due block signaling pathways extracellular signal‐controlled kinase (MAPK/ERK) proteasome (PI3K/AKT/mTOR). can inhibit cell division various androgen receptor (AR), a protein that is required for growth dissemination prostate cancer. It initiates caspase cascade obstructs production new proteins lung These colon entering G2/M cycle phase inducing apoptosis. also known cyclin‐dependent 2 cyclin B1, two related an enhanced risk suppress breakdown B1 CDK2 stop development Preclinical evidence consistently supports efficacy suppressing tumor growth; however, human clinical trials show variability differences bioavailability, metabolism, dosage. Despite promise alternative or adjunctive therapies, limitations such low solubility, interindividual metabolic variations, inconsistent outcomes necessitate further large‐scale, controlled trials. Future research should focus on improving bioavailability exploring synergistic effects with conventional therapies.

Language: Английский

A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma DOI Creative Commons
Huan Chen, Ting Li, Xiaogang Li

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Feb. 20, 2023

Abstract The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor sites accurately and properly activate complex immune responses. Herein, we design prepare a kind chemotactic nanomotor loaded with brain endothelial cell targeting agent angiopep-2 anti-tumor drug (Lonidamine modified mitochondrial triphenylphosphine, TLND). Reactive oxygen species inducible nitric oxide synthase (ROS/iNOS), which specifically highly expressed in microenvironment, used as chemoattractants to induce the behavior nanomotors. We propose precise strategy cells-tumor cells-mitochondria. Results verified released NO TLND can regulate circulation through multiple steps enhance effect immunotherapy, including triggering immunogenic death tumor, inducing dendritic cells mature, promoting cytotoxic T infiltration, regulating microenvironment. Moreover, this treatment form an effective memory prevent metastasis recurrence.

Language: Английский

Citations

98
Unraveling the impact of miR-21 on apoptosis regulation in glioblastoma DOI
Mohammad Arshad Javed Shaikh, Abdulmalik Saleh Alfawaz Altamimi, Muhammad Afzal

et al.

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 254, P. 155121 - 155121

Published: Jan. 10, 2024

Language: Английский

Citations

21
Clustering Functional Magnetic Resonance Imaging Time Series in Glioblastoma Characterization: A Review of the Evolution, Applications, and Potentials DOI Creative Commons
Matteo De Simone, Giorgio İaconetta, Giuseppina Palermo

et al.

Brain Sciences, Journal Year: 2024, Volume and Issue: 14(3), P. 296 - 296

Published: March 20, 2024

In this paper, we discuss how the clustering analysis technique can be applied to analyze functional magnetic resonance imaging (fMRI) time-series data in context of glioblastoma (GBM), a highly heterogeneous brain tumor. The precise characterization GBM is challenging and requires advanced analytical approaches. We have synthesized existing literature provide an overview algorithms help identify unique patterns within dynamics GBM. Our review shows that fMRI time series has great potential for improving differentiation between various subtypes GBM, which pivotal developing personalized therapeutic strategies. Moreover, method proves effective capturing temporal changes occurring enhancing monitoring disease progression response treatment. By thoroughly examining consolidating current research, paper contributes understanding techniques refine This article emphasizes importance incorporating cutting-edge into neuroimaging neuro-oncology research. providing detailed perspective, approach may guide future investigations boost development tailored strategies

Language: Английский

Citations

18
Metabolism/Immunity Dual‐Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate‐Excretion Inhibition and PD‐1/PD‐L1 Blockade DOI Creative Commons
Tianliang Li, Dan Xu,

Zhao Ruan

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(18)

Published: March 9, 2024

Abstract Intrinsic immunosuppressive tumor microenvironment (ITM) and insufficient infiltration of T cells severely impede the progress glioblastoma (GBM) immunotherapy. In this study, it is identify that inhibiting expression glucose transporter 1 (GLUT1) can facilitate prevention lactate excretion from glycolysis, which significantly alleviates lactate‐driven ITM by reducing tumor‐associated macrophages (TAMs) regulatory (Tregs). Simultaneously, findings show generated inflammatory cytokine IFN‐γ during immune activation aggravates escape upregulating checkpoint programmed death‐ligand (PD‐L1) in TAMs. Therefore, an injectable thermogel loaded with a GLUT1 inhibitor BAY‐876 PD‐1/PD‐L1 blocker BMS‐1 (Gel@B‐B) for dual‐regulation metabolism immunity GBM developed. Consequently, situ injection Gel@B‐B delays growth prolongs survival orthotopic mouse model. By actively exposing antigens to antigen‐presenting cells, vaccine combined found increase fraction effector (Th1/CTLs) microenvironment, thereby remarkably mitigating recurrence long‐term. This study may provide promising strategy

Language: Английский

Citations

16
Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes DOI Open Access
Dávid Sipos, Bence L. Raposa, Omar Freihat

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(1), P. 146 - 146

Published: Jan. 5, 2025

Glioblastoma, the most common and aggressive primary brain tumor in adults, presents a formidable challenge due to its rapid progression, treatment resistance, poor survival outcomes. Standard care typically involves maximal safe surgical resection, followed by fractionated external beam radiation therapy concurrent temozolomide chemotherapy. Despite these interventions, median remains approximately 12–15 months, with five-year rate below 10%. Prognosis is influenced factors such as patient age, molecular characteristics, extent of resection. Patients IDH-mutant tumors or methylated MGMT promoters generally have improved survival, while recurrent glioblastoma associated only six therapies cases are often palliative. Innovative treatments, including TTFields, add incremental benefits, extending around 20.9 months for eligible patients. Symptom management—addressing seizures, headaches, neurological deficits—alongside psychological support patients caregivers essential enhance quality life. Emerging targeted immunotherapies, though still limited efficacy, show promise part an evolving landscape. Continued research clinical trials remain crucial developing more effective treatments. This multidisciplinary approach, incorporating diagnostics, personalized therapy, supportive care, aims improve outcomes provides hopeful foundation advancing management.

Language: Английский

Citations

2
Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma DOI Creative Commons

Zhongzheng Sun,

Yongquan Zhao,

Wei Yan

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Aug. 25, 2022

Background Glioblastoma (GBM) is the most prominent and aggressive primary brain tumor in adults. Anoikis a specific form of programmed cell death that plays key role invasion metastasis. The presence anti-anoikis factors associated with aggressiveness drug resistance. Methods non-negative matrix factorization algorithm was used for effective dimension reduction integrated datasets. Differences microenvironment (TME), stemness indices, clinical characteristics between two clusters were analyzed. Difference analysis, weighted gene coexpression network analysis (WGCNA), univariate Cox regression, least absolute shrinkage selection operator regression leveraged to screen prognosis-related genes construct risk score model. Immunohistochemistry performed evaluate expression representative specimens. relationship TME, stemness, traits, immunotherapy response assessed GBM pancancer. Results Two definite identified on basis anoikis-related expression. Patients assigned C1 characterized by shortened overall survival, higher suppressive immune infiltration levels, lower indices. We further constructed scoring model quantify regulatory patterns genes. group poor prognosis, cells differentiated phenotype, whereas exhibited opposite effects. In addition, patients frequency isocitrate dehydrogenase (IDH) mutations more sensitive immunotherapy. Drug sensitivity performed, revealing may benefit from drugs targeting PI3K/mTOR signaling pathway. Conclusion revealed potential relationships features, IDH mutation, elucidated their therapeutic value.

Language: Английский

Citations

69
LncRNA NEAT1 facilitates glioma progression via stabilizing PGK1 DOI Creative Commons
Jingshan Liang, Changtao Liu,

Dezhi Xu

et al.

Journal of Translational Medicine, Journal Year: 2022, Volume and Issue: 20(1)

Published: Feb. 5, 2022

Abstract Background Long noncoding RNA NEAT1 has been implicated in glioma progression. However, the effect of on glycolysis cell and potential mechanism remain unclear. Methods In vitro experiments, including CCK-8, colony formation, ECAR, lactate detection assays were performed to evaluate proliferation cell. pulldown RIP identify interaction between PGK1. Truncated mutation PGK1 was used confirm specific interactive domains Animal studies analyze NEAT1/PGK1 Results knockdown significantly suppressed cells. could specifically interact with PGK1, which promotes stability. Hairpin A is essential for M1 domain Depletion markedly inhibited tumor growth mice, while reverse this effect. Higher expression associated poor overall survival GBM patients. Conclusions over progression through stabilizing axis a candidate therapeutic target treatment.

Language: Английский

Citations

52
Nanoparticle-Based Drug Delivery Systems: An Inspiring Therapeutic Strategy for Neurodegenerative Diseases DOI Open Access

Linyan Duan,

Xingfan Li,

Rong Ji

et al.

Polymers, Journal Year: 2023, Volume and Issue: 15(9), P. 2196 - 2196

Published: May 5, 2023

Neurodegenerative diseases are common, incurable neurological disorders with high prevalence, and lead to memory, movement, language, intelligence impairments, threatening the lives health of patients worldwide. The blood–brain barrier (BBB), a physiological between central nervous system peripheral blood circulation, plays an important role in maintaining homeostasis intracerebral environment by strictly regulating transport substances brain. Therefore, it is difficult for therapeutic drugs penetrate BBB reach brain, this affects their efficacy. Nanoparticles (NPs) can be used as drug carriers also known nanoparticle-based delivery systems (NDDSs). These not only increase stability but facilitate crossing through improve In article, we provided overview types administration routes NPs, highlighted preclinical clinical studies NDDSs neurodegenerative diseases, summarized combined strategies management diseases. Finally, prospects challenges recent basic research were discussed. Above all, provide inspiring strategy treatment

Language: Английский

Citations

41
Impact of age and gender on glioblastoma onset, progression, and management DOI
Ambra Colopi,

Serena Fuda,

Samuele Santi

et al.

Mechanisms of Ageing and Development, Journal Year: 2023, Volume and Issue: 211, P. 111801 - 111801

Published: March 28, 2023

Language: Английский

Citations

36
The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma DOI Open Access
Linyong Shi, Hanning Chen, Kunxiang Chen

et al.

Clinical Cancer Research, Journal Year: 2023, Volume and Issue: 29(16), P. 3172 - 3188

Published: May 30, 2023

Temozolomide resistance remains a major obstacle in the treatment of glioblastoma (GBM). The combination temozolomide with another agent could offer an improved option if it overcome chemoresistance and prevent side effects. Here, we determined critical drug that cause ferroptosis GBM cells elucidated possible mechanism by which overcomes chemoresistance.Haloperidol/temozolomide synergism was assessed cell lines different dopamine D2 receptor (DRD2) expression vitro vivo. Inhibitors ferroptosis, autophagy, endoplasmic reticulum (ER) stress cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) were used to validate specific mechanisms haloperidol induce cells.In present work, demonstrate DRD2 level is increased time-dependent manner inversely correlated sensitivity GBM. antagonist haloperidol, butylbenzene antipsychotic, markedly induces effectively enhances efficacy vivo vitro. Mechanistically, suppressed effect on cAMP antagonizing activity, increases cAMP/PKA triggered ER stress, led autophagy ferroptosis. Furthermore, elevated mediates downregulation FTH1 at posttranslational autophagy-dependent ultimately leads ferroptosis.Our results provide experimental evidence for repurposing as effective adjunct therapy inhibit adaptive enhance chemoradiotherapy GBM, strategy may have broad prospects clinical application.

Language: Английский

Citations

33